The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 24, 2012
Filed:
Feb. 19, 2009
Liliane Goetsch, Ayze, FR;
Nathalie Corvaia, Archamps, FR;
Alain Duflos, Labruguiere, FR;
Jean-francois Haeuw, St. Julien En Genevois, FR;
Olivier Leger, Annemasse, FR;
Alain Beck, Collonges Sous Saleve, FR;
Liliane Goetsch, Ayze, FR;
Nathalie Corvaia, Archamps, FR;
Alain Duflos, Labruguiere, FR;
Jean-Francois Haeuw, St. Julien En Genevois, FR;
Olivier Leger, Annemasse, FR;
Alain Beck, Collonges Sous Saleve, FR;
Pierre Fabre Medicament, Boulogne-Billancourt, FR;
Abstract
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.